ACR 2017 Conference Correspondent
Sustained Response in TARGET Study of Sarilumab + csDMARDs versus Placebo in RA Patients with Inadequate Response to TNF Inhibitors
The phase 3 TARGET study demonstrated that sarilumab (150 or 200 mg subcutaneously every 2 weeks [q2w]) plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) achieved clinical responses in terms of rheumatoid arthritis (RA) signs and symptoms and physical function compared with placebo in adults with active, moderate-to-severe RA who were intolerant of, or showed inadequate response to, tumor necrosis factor (TNF) inhibitors.
Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA
The current study examines whether high cTnI also predicts incident long-term cardiovascular (CV) events and optimizes CV risk stratification in the Prospective Evaluation of Lateral Coronary Atherosclerosis in RA (PROTECT-RA) trial after 5 years of follow-up.
Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment
The phase 3 SIRROUND-D trial demonstrated that sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, resulted in significant reduction in rheumatoid arthritis (RA) signs and symptoms, and inhibited radiographic progression at week 52 compared with placebo in patients with active RA despite disease-modifying antirheumatic drug (DMARD) treatment.
Sarilumab + csDMARDs Effective Regardless of Baseline Disease Activity in RA Patients with Inadequate Response to TNF Inhibitors
Sarilumab, a human monoclonal antibody that inhibits interleukin (IL)-6–mediated signaling by blocking IL-6 receptor alpha, is currently approved for the treatment of moderately to severely active rheumatoid arthritis (RA).
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
The efficacy and safety of sarilumab, a human monoclonal antibody blocking the interleukin-6 receptor alpha, were evaluated for treatment of rheumatoid arthritis (RA) in 3 clinical trials, including the MOBILITY trial.
This analysis of the MOBILITY and TARGET studies showed that patients treated with sarilumab achieved responses as early as week 4, and that ongoing sarilumab treatment resulted in achievement of remission or LDA through week 24, with additional increases seen through week 52 (MOBILITY).
The current study reported on updated integrated safety data from 8 randomized trials that further described the safety profile for up to 5.5 years of baricitinib in adult patients with moderately to severely active RA.
Page 2 of 2
Results 11 - 19 of 19
Results 11 - 19 of 19